Abstract
More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Current Drug Therapy
Title:Cancer Metastasis Treatments
Volume: 8 Issue: 1
Author(s): Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu and Shan Cao
Affiliation:
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Abstract: More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren, Wu Hong-Ying and Cao Shan, Cancer Metastasis Treatments, Current Drug Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574885511308010003
DOI https://dx.doi.org/10.2174/1574885511308010003 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Cancer Therapy Reviews Challenges and Solutions in the Development of Genomic Biomarker Panels: A Systematic Phased Approach
Current Genomics Editorial [Hot Topic: ADAMs: Targets for Drug Discovery (Executive Editor: Marcia L. Moss)]
Current Pharmaceutical Design In Vivo Monitoring of Cell Based Therapy in the Liver
Current Molecular Imaging (Discontinued) Combined Modality Treatment of Limited Stage Small Cell Carcinoma of the Lung
Reviews on Recent Clinical Trials Synthesis and Preliminary Screening of Novel A- and D-Ring Modified Steroids as Aromatase Inhibitors
Letters in Drug Design & Discovery Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Modern Therapeutic Antibody Drug Discovery Technologies)
Current Drug Discovery Technologies Protective Role of Natural Products in Cisplatin-Induced Nephrotoxicity
Mini-Reviews in Medicinal Chemistry Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas
Anti-Cancer Agents in Medicinal Chemistry Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets Patent Selections
Recent Patents on Regenerative Medicine SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Metabolism of Flavonoids in Human: A Comprehensive Review
Current Drug Metabolism Trefoil Factor Family (TFF) Peptides and their Different Roles in the Mucosal Innate Immune Defense and More: An Update
Current Medicinal Chemistry Diverse Therapeutic Potential of Nitidine, A Comprehensive Review
Current Drug Metabolism Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Current Cancer Drug Targets